Enovis Beheer

Beheer criteriumcontroles 3/4

De CEO Enovis is Matt Trerotola, benoemd in Jul2015, heeft een ambtstermijn van 9.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.77M, bestaande uit 10% salaris en 90% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.32% van de aandelen van het bedrijf, ter waarde $ 8.31M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 4.3 jaar.

Belangrijke informatie

Matt Trerotola

Algemeen directeur

US$10.8m

Totale compensatie

Percentage CEO-salaris	10.0%
Dienstverband CEO	9.3yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	5.8yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Matt Trerotola's beloning veranderd ten opzichte van Enovis's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 27 2024	n/a	n/a	-US$121m
Jun 28 2024	n/a	n/a	-US$107m
Mar 29 2024	n/a	n/a	-US$103m
Dec 31 2023	US$11m	US$1m	-US$54m
Sep 29 2023	n/a	n/a	-US$112m
Jun 30 2023	n/a	n/a	-US$159m
Mar 31 2023	n/a	n/a	-US$23m
Dec 31 2022	US$12m	US$1m	-US$39m
Sep 30 2022	n/a	n/a	US$1m
Jul 01 2022	n/a	n/a	US$54m
Apr 01 2022	n/a	n/a	-US$109m
Dec 31 2021	US$14m	US$1m	-US$103m
Oct 01 2021	n/a	n/a	-US$48m
Jul 02 2021	n/a	n/a	-US$18m
Apr 02 2021	n/a	n/a	US$21m
Dec 31 2020	US$8m	US$1m	-US$75m
Oct 02 2020	n/a	n/a	US$53m
Jul 03 2020	n/a	n/a	US$39m
Apr 03 2020	n/a	n/a	US$42m
Dec 31 2019	US$8m	US$1m	US$8m
Sep 27 2019	n/a	n/a	US$10m
Jun 28 2019	n/a	n/a	US$21m
Mar 29 2019	n/a	n/a	US$66m
Dec 31 2018	US$3m	US$1m	US$108m
Sep 28 2018	n/a	n/a	-US$115m
Jun 29 2018	n/a	n/a	-US$84m
Mar 30 2018	n/a	n/a	-US$92m
Dec 31 2017	US$3m	US$1m	US$28m

Compensatie versus markt: De totale vergoeding ($USD 10.77M ) Matt } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.60M ).

Compensatie versus inkomsten: De vergoeding van Matt is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Matt Trerotola (57 yo)

9.3yrs

Tenure

US$10,774,635

Compensatie

Mr. Matthew L. Trerotola, also known as Matt, has been the Chief Executive Officer of Enovis Corporation (formerly known as Colfax Corporation) since July 24, 2015 and had been its President from July 2015...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Matthew Trerotola	CEO & Chairman	9.3yrs	US$10.77m	0.32% $ 8.3m
Phillip Berry	Senior VP & CFO	1.8yrs	US$2.36m	0.063% $ 1.6m
Patricia Lang	Senior VP & Chief Human Resources Officer	5.8yrs	US$2.07m	0.040% $ 1.0m
Daniel Pryor	Executive Vice President of Strategy & Business Development	11.3yrs	US$4.75m	0.15% $ 4.0m
Brady Shirley	Executive Advisor & Director	8yrs	US$5.20m	0.11% $ 2.9m
John Kleckner	VP, Controller & Chief Accounting Officer	2.5yrs	geen gegevens	0.012% $ 300.6k
Derek Leckow	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Bradley Tandy	Senior VP & Chief Legal Officer	5.8yrs	geen gegevens	0.045% $ 1.2m
Katie Sweet	Vice President of Corporate Communication	no data	geen gegevens	geen gegevens
Tim Czartoski	President of U.S. Surgical and Global Product & Enabling Technologies	less than a year	geen gegevens	geen gegevens
Terry Ross	Group President Prevention & Recovery	no data	geen gegevens	0.035% $ 912.2k
Brian Hanigan	Secretary	no data	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ENOV is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Matthew Trerotola	CEO & Chairman	9.3yrs	US$10.77m	0.32% $ 8.3m
Brady Shirley	Executive Advisor & Director	2.6yrs	US$5.20m	0.11% $ 2.9m
Sharon Wienbar	Lead Independent Director	8.4yrs	US$316.46k	0% $ 0
A. Perfall	Independent Director	14.2yrs	US$308.93k	0.0044% $ 115.1k
Angela Lalor	Independent Director	2.6yrs	US$296.46k	0.022% $ 562.9k
Rajiv Vinnakota	Independent Director	16.5yrs	US$298.93k	0.039% $ 1.0m
Liam Kelly	Independent Director	4.8yrs	US$283.93k	0.023% $ 603.3k
Philip Okala	Independent Director	3.8yrs	US$283.93k	0.015% $ 383.0k
Barbara Bodem	Independent Director	2.6yrs	US$283.93k	0.015% $ 383.0k
Christine Ortiz	Independent Director	2.6yrs	US$283.93k	0.015% $ 383.0k

4.3yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ENOV wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Enovis Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Enovis Corp Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

Enovis Corporation, Annual General Meeting, May 20, 2024

Enovis Corporation Announces Leadership Transition Plan

Independent Director notifies of intention to sell stock

High number of new directors

Enovis Corporation Announces That Ben Berry, CFO of the Company's Business Units, Will Succeed Chris Hix as Chief Financial Officer, Effective January 1, 2023

Recent updates

Consensus EPS estimates fall by 13%

Third quarter 2024 earnings: EPS misses analyst expectations

Enovis Corporation Narrows Earnings Guidance for the Year 2024

Enovis Corporation to Report Q3, 2024 Results on Nov 06, 2024

Price target decreased by 7.1% to US$67.00

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Enovis Corp Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

Enovis Continues to Redefine Revision Knee Surgery with the Addition of Emowr Revision Knee

It's A Story Of Risk Vs Reward With Enovis Corporation (NYSE:ENOV)

Enovis Corporation Introduces Star Ankle, Now with E+ Polyethylene for Unmatched Durability

Consensus EPS estimates fall by 20%

Second quarter 2024 earnings: EPS misses analyst expectations

Enovis Corporation Narrows Revenue Guidance for the Year 2024

Enovis Corporation to Report Q2, 2024 Results on Aug 07, 2024

Enovis Languishing Despite Respectable Performance

Enovis Releases AltiVate Reverse Glenoid System, Widening Range of Patients Who May Be Treated with AltiVate Reverse

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Enovis: Solid Growth, But Unstable Financial Footing

Enovis Corporation Updates Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Enovis Corporation (NYSE:ENOV) Might Not Be As Mispriced As It Looks

Enovis Corporation to Report Q1, 2024 Results on May 02, 2024

Enovis Corporation, Annual General Meeting, May 20, 2024

Price target increased by 8.6% to US$75.20

Full year 2023 earnings: EPS exceeds analyst expectations

Enovis Corporation Provides Earnings Guidance for the Year 2024

Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation to Report Q4, 2023 Results on Feb 22, 2024

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

Is Enovis (NYSE:ENOV) Using Too Much Debt?

Investors Holding Back On Enovis Corporation (NYSE:ENOV)

Enovis Corporation Announces Leadership Transition Plan

Consensus EPS estimates fall by 87%

No longer forecast to breakeven

Calculating The Fair Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation to Report Q3, 2023 Results on Nov 07, 2023

Enovis Making Good Choices, But Not Seeing The Rewards

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Is Enovis (NYSE:ENOV) A Risky Investment?

New major risk - Revenue and earnings growth

Enovis Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation: Things Are Looking Good As Guidance Is Raised

Enovis Corporation to Report Q2, 2023 Results on Aug 03, 2023

Price target increased by 8.0% to US$68.17

Enovis Corporation (NYSE:ENOV) acquired Novastep Inc. from Amplitude Surgical SA (ENXTPA:AMPLI).

Forecast breakeven date pushed back to 2024

We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt

Independent Director notifies of intention to sell stock

Enovis Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS misses analyst expectations

Enovis Corporation Q4 2022 Earnings Preview

Is Enovis (NYSE:ENOV) A Risky Investment?

Enovis Corporation to Report Q4, 2022 Results on Feb 23, 2023

Is Enovis Corporation (NYSE:ENOV) Worth US$60.5 Based On Its Intrinsic Value?

Enovis Corporation Announces the Launch of the Dynaclip Delta and Dynaclip Quattro Bone Staples

Enovis Receives FDA Approval of Patient Specific Instrumentation for STAR Ankle

Enovis Corporation Announces Introduction of DynaNail Helix

High number of new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Enovis Corporation Provides Earnings Guidance for the Year 2022

Enovis Corporation reports Q3 earnings beat; updates FY22 guidance

Is Enovis (NYSE:ENOV) A Risky Investment?

Now 21% undervalued after recent price drop

Enovis Corporation to Report Q3, 2022 Results on Nov 02, 2022

Is Enovis Corporation (NYSE:ENOV) Trading At A 27% Discount?